Immunotherapy is changing the way we perceive and treat cancer. Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the power of the immune system to fight disease. We are witnessing the emergence of a new vision within the cancer treatment landscape – one that is having an immediate and powerful impact on cancer patients everywhere.
During this year’s State of the Union address, President Barack Obama announced Cancer Moonshot 2020: a new initiative aimed at eliminating cancer as we know it. Cancer Moonshot 2020 plans to break down barriers and enable progress by enhancing data access, facilitating collaborations, and investing in the development of new technologies and treatments. We applaud this initiative not only for its emphasis on eliminating the burden of cancer, but also for its practical approaches and acknowledgement of the complexities of this mission.
By Punit Dhillon, CEO and President of OncoSec Medical Incorporated
After the conclusion of several conferences this past month, I’ve had time to reflect on key takeaways and principal trends emerging in the healthcare sector. Despite less than stellar market conditions, speakers at conferences (such as J.P. Morgan 2016 and Bio CEO) and ancillary events remained optimistic and highlighted important insights into the future of healthcare. After a busy schedule with non-stop meetings and presentations, I returned home confident in OncoSec’s place in the burgeoning cancer immunotherapy landscape. Continue reading “Bridging Connections and Insights from Investment Conferences”
On behalf of the OncoSec team, we’re thrilled to announce the first patient enrolled in the Phase II Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) to assess the safety and efficacy of the combination of our investigational therapy, ImmunoPulse™ IL-12, and Merck’s approved anti-PD-1 agent, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma.
We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market. This marks an exciting and significant milestone for our company as we continue to build on our success and advance our technologies to one day benefit patients everywhere.
On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.
On behalf of OncoSec, I want to thank our shareholders for their ongoing support of our mission to develop novel intratumoral immunotherapies to treat cancer. To date, the company has never been stronger in terms of our ImmunoPulse™ technology, advanced clinical pipeline, and collaborations with academic and industry institutions.